Comparative Pharmacology
Head-to-head clinical analysis: PONATINIB HYDROCHLORIDE versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONATINIB HYDROCHLORIDE versus PONLIMSI.
PONATINIB HYDROCHLORIDE vs PONLIMSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
45 mg orally once daily with or without food.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor